Quantum Biopharma Appoints New CEO to Drive Market Expansion

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Apr 22 2026

0mins

Should l Buy QNTM?

Source: Newsfilter

Quantum Biopharma Ltd's stock surged by 24.93% as it crossed above the 20-day SMA, reflecting strong investor interest following the appointment of Richard Buzbuzian as CEO.

The appointment marks a pivotal milestone in the company's strategy to capitalize on the projected $198 billion functional beverage market by 2026. With a unique formulation that accelerates alcohol metabolism, Quantum's product, unbuzzd, meets the growing demand for health-focused beverages, enhancing consumer trust and investor confidence. The company plans a nationwide rollout across various retail channels, aiming to capture significant market share.

This leadership change is expected to drive Quantum's growth and innovation in the competitive beverage market, positioning the company for future success.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy QNTM?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on QNTM

About QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Quantum BioPharma Announces Marketing Partnerships for Investor Awareness

Apr 28 2026Newsfilter

Marketing Partnerships: Quantum BioPharma has signed a one-month contract with Senergy Communications for $150,000 to enhance corporate branding and investor awareness through social media and advertising initiatives, aiming to boost market presence.
Investor Relations Enhancement: Concurrently, Quantum has engaged King Tide Media for $125,000 to foster ongoing dialogues with shareholders and market participants, further increasing the company's visibility in the biopharmaceutical sector.
Innovative Drug Development: Quantum BioPharma is focused on developing Lucid-MS, a new chemical entity that has shown potential to prevent and reverse myelin degradation in preclinical models, targeting neurodegenerative diseases like multiple sclerosis.
Equity Structure Transparency: Quantum retains a 19.84% stake in Unbuzzd Wellness Inc. and has established a 7% royalty agreement on sales, which is expected to generate significant long-term revenue for the company.